The 6th Annual North Carolina Research Triangle Pulmonary Hypertension Symposium will be held on November 7th at the DoubleTree by Hilton Hotel Raleigh-Durham Airport in Research Triangle Park, from 7am to 4pm. The event is endorsed by the American Thoracic Society, sponsored by the Duke University School of…
Clinical application of sildenafil, a phosphodiesterase inhibitor studied for efficacy in treating pulmonary hypertension, to a patient with systemic sclerosis gave meaningful data that support results of basic laboratory research on sildenafil. The patient, a 40 year old female with diffuse…
Promedior Inc., a clinical stage biotechnology company developing novel therapeutics for the treatment of fibrosis, has announced that retrospective quantitative imaging data from the company’s Phase 1b clinical trial of the drug PRM-151 for treatment of idiopathic pulmonary fibrosis (IPF), was presented in a poster at the 18th…
New research suggests administering molecular Hydrogen, an antioxidant, orally via Hydrogen water may offer therapeutic value to Pulmonary Hypertension patients. Pulmonary hypertension (PH) is a condition caused by increased pressure in the pulmonary arteries. In advanced cases, its symptoms (shortness of breath, tiredness, chest pain) worsen and may limit…
New insights into the molecular mechanisms of chronic thromboembolic pulmonary hypertension (CTEPH) and idiopathic pulmonary arterial hypertension (iPAH) generally lead to new avenues of research for treatments that may work better than existing treatments or open the doors for previously untreatable patients. Work from Medical University Vienna in Austria,…
A team of scientists recently reported that patients with both pulmonary arterial hypertension and congenital heart disease (PAH-CHD) exhibit Quality of Life (QoL) scores significantly lower when compared to patients with stable PAH. The data were presented at the European Respiratory Society (ERS) Annual Congress. For this study,…
The Pulmonary Hypertension Association has announced that it is launching a new PHA Patient Telephone Support Group to help patients who suffer from pulmonary hypertension (PH). The support group will offer support to patients, especially those who were recently diagnosed, and will consist of monthly telephone dialogues for…
FibroGen Inc. will present the full data set from a clinical study of patients with Idiopathic Pulmonary Fibrosis (IPF), treated for 48 weeks with the company’s investigational drug FG-3019, at the 18th International Colloquium on Lung and Airway Fibrosis (ICLAF) in progress this week at Mont Tremblant, Quebec…
A new study published in the September issue of BMC Pulmonary Medicine reports that pulmonary hypertension is among the main lung diseases associated with non specific pattern (NSP), a condition characterized by normal total lung capacity (TLC) but an increased residual volume (RV). The study is entitled “Non…
The Pulmonary Hypertension Association (PHA) is hosting their annual educational event “PHA On The Road,” a free educational forum to help both pulmonary hypertension (PH) patients and their families and caregivers fight the rare lung disease, which affects blood pressure in the lungs, and with no…
Despite the widely held observation that inflammation leads to deadly scarring in idiopathic pulmonary fibrosis, according to a new study conducted at the National Jewish Health, some inflammation may help in the healing and repair process of the lung. Assistant professor of cell biology Elizabeth Redente, PhD, and her research team discovered…
A new study, entitled “Vascular Receptor Autoantibodies in Pulmonary Arterial Hypertension Associated with Systemic Sclerosis,” conducted at Charité University Hospital, Rheumatology and Clinical Immunology in Berlin, Germany, and published in the American Journal of Respiratory and Critical Care Medicine by first author on the study Dr. Mike…
Get regular updates to your inbox.